Vera Therapeutics, Inc. (VERA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Brisbane, CA, United States. The current CEO is Marshall W. Fordyce.
VERA has IPO date of 2021-05-14, 152 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $3.17B.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for serious immunological diseases in the United States. The company's lead candidate, atacicept, is a fusion protein administered via subcutaneous injection currently in Phase IIb trials for immunoglobulin A nephropathy. Vera is also advancing MAU868, a monoclonal antibody in Phase 2 development for treating BK viremia infections. Founded in 2016 and headquartered in Brisbane, California, the company was previously known as Trucode Gene Repair, Inc. before rebranding as Vera Therapeutics in April 2020.
